Global Clinical Data Exchanges And Research Dependency Risks

1. Introduction

Global clinical data exchanges are cross-border systems through which clinical-trial data, patient-level datasets, genomic information, electronic health records, real-world evidence, safety information, and research datasets are shared among pharmaceutical companies, biotechnology firms, hospitals, universities, contract research organisations (CROs), regulators, data platforms, and research consortia.

These exchanges can substantially improve medical research by enabling:

• larger and more representative datasets;
• faster clinical-trial recruitment;
• comparative effectiveness research;
• rare-disease research;
• pharmacovigilance;
• precision medicine;
• AI and machine-learning development; and
• international regulatory cooperation.

However, research dependency risks arise when access to clinically valuable data becomes concentrated in a small number of institutions, platforms, technology providers, hospitals, pharmaceutical companies, or data intermediaries. Researchers may become dependent upon a particular data source, interoperability standard, analytics platform, or permission system.

The competition-law problem is therefore broader than a conventional “data monopoly.” The central question is:

Can control over indispensable clinical data or the infrastructure through which clinical data is exchanged create or reinforce market power, restrict scientific competition, or make independent research dependent upon dominant intermediaries?

2. Meaning of Clinical Data Exchanges

A clinical data exchange may involve several layers:

A. Data generation

Data originates from:

• hospitals;
• clinical trials;
• laboratories;
• wearable devices;
• genomic sequencing;
• pharmacies;
• insurance systems;
• electronic health records;
• patient registries.

B. Data aggregation

A platform or intermediary may combine data from multiple sources.

C. Data standardisation

Data can be converted into common formats such as:

• FHIR;
• HL7;
• CDISC;
• SNOMED CT;
• ICD;
• OMOP common data model.

D. Data access

Researchers may receive:

• identifiable information;
• pseudonymised information;
• anonymised datasets;
• aggregate statistics;
• secure-query access; or
• federated-learning access.

E. Analytics infrastructure

Data may be processed through:

• cloud computing;
• AI systems;
• statistical platforms;
• clinical-trial management systems; and
• research databases.

Thus, dependency can arise at any layer of the clinical-data ecosystem.

3. Why Clinical Data Can Become a Strategic Competitive Asset

Clinical data possesses several characteristics that can make it commercially and scientifically valuable.

3.1 Scarcity

Some datasets cannot easily be reproduced.

For example, a dataset concerning a rare disease may require:

• decades of observations;
• specialised hospitals;
• international patient participation;
• longitudinal records; and
• substantial research expenditure.

A rival cannot necessarily recreate it merely by investing money.

3.2 Cumulative value

The value of clinical data can increase when additional datasets are added.

A platform possessing:

10 hospitals → 100 hospitals → 1,000 hospitals

may obtain increasingly valuable analytical capabilities.

This can generate data-network effects.

3.3 Switching costs

Researchers may invest heavily in:

• software;
• data schemas;
• APIs;
• training;
• statistical pipelines;
• validation;
• regulatory documentation.

Once these systems are built around one provider, switching becomes expensive.

4. Research Dependency

Research dependency occurs where researchers or research institutions cannot realistically conduct equivalent work without access to a particular dataset or infrastructure.

It can arise through:

Data dependency

Researchers need access to a particular dataset.

Infrastructure dependency

Researchers need a particular cloud, database or exchange platform.

Interoperability dependency

Researchers must use the dominant platform's technical standard.

Analytical dependency

Researchers depend upon the platform's proprietary algorithms.

Regulatory dependency

Regulatory approval or compliance may require access to a particular data environment.

Network dependency

The usefulness of a platform increases because most hospitals, researchers and pharmaceutical companies already participate in it.

5. Competition-Law Concerns

5.1 Refusal to provide access

A dominant clinical-data platform might refuse access to independent researchers.

The legal question is whether the data constitutes an essential facility or indispensable input.

Ordinarily, competition law does not require a company to share its assets with competitors. But exceptional circumstances can arise where:

1. access is indispensable;
2. duplication is impossible or economically unrealistic;
3. refusal eliminates effective competition; and
4. there is no objective justification.

6. Case Law

Case 1: IMS Health GmbH & Co. OHG v NDC Health GmbH

Court: Court of Justice of the European Union
Year: 2004
Citation: C-418/01

This is one of the most important cases for understanding competition law and proprietary information infrastructure.

IMS Health operated a pharmaceutical-sales information system using a detailed regional segmentation system. A competitor sought access to the structure because pharmaceutical companies had become accustomed to using it.

The CJEU established stringent conditions for treating refusal to license or provide access to an intellectual-property-related resource as abusive.

The Court identified circumstances including:

• indispensability;
• elimination of effective competition;
• prevention of a new product for which consumer demand exists; and
• absence of objective justification.

Relevance to clinical data

A clinical-data exchange may similarly become deeply embedded in research practices.

If:

hospitals → researchers → pharmaceutical companies → regulators

all rely upon one data structure, the exchange could potentially acquire characteristics analogous to an indispensable infrastructure.

However, mere usefulness is insufficient. The IMS Health standard is deliberately demanding.

7. Case 2: Bronner v Mediaprint

Court: CJEU
Year: 1998
Citation: C-7/97

The Court considered whether access to a dominant newspaper's distribution system had to be provided to a competitor.

The Court required a high threshold for an essential-facilities theory.

The resource must be effectively indispensable, meaning that there must be no realistic alternative.

Application

Suppose a global clinical-data exchange controls access to a unique rare-disease dataset.

A competition authority would need to ask:

• Are alternative datasets available?
• Can researchers generate equivalent data?
• Can another exchange be created?
• How long would replication take?
• Would replication be economically viable?

The case therefore prevents competition law from converting every valuable database into a mandatory-access facility.

8. Case 3: Slovak Telekom v Commission

Court: CJEU
Year: 2021
Cases: C-165/19 P and C-166/19 P

The litigation concerned access to telecommunications infrastructure and the relationship between Article 102 TFEU and refusal-to-supply principles.

The judgment reinforced the importance of analysing the specific regulatory and competitive circumstances surrounding access obligations.

Clinical-data significance

Where clinical-data infrastructure is subject to extensive regulation or access obligations, the competition-law analysis may differ from an ordinary proprietary database.

For example:

regulatory interoperability obligation + dominant exchange + discriminatory access

can create a substantially stronger competition concern than simple refusal to license privately created data.

9. Case 4: Microsoft Corp. v Commission

Court: General Court of the European Union
Year: 2007
Case: T-201/04

Microsoft was found to have abused its dominant position by restricting interoperability information necessary for competitors to operate effectively with Microsoft's dominant systems.

Importance for clinical-data exchanges

The case demonstrates that interoperability itself can become a competitive resource.

A clinical-data platform could potentially create dependency by withholding:

• API documentation;
• interoperability protocols;
• technical specifications;
• authentication mechanisms;
• data-mapping information.

The competition issue is therefore not limited to possession of raw patient data.

Control over the technical gateway to data can also create market power.

10. Case 5: Google Shopping

Court: General Court / CJEU
Year: 2024 confirmation on appeal
Core case: Google and Alphabet v Commission

The Google Shopping litigation concerned Google's conduct in favouring its own comparison-shopping service within its general search results.

The broader lesson is that a dominant platform can potentially use control over a critical gateway to advantage its own downstream activities.

Clinical-data application

Imagine a dominant clinical-data exchange that operates:

1. a data-access platform;
2. an AI research service; and
3. a pharmaceutical analytics business.

If the platform gives its own research service preferential access to:

• faster queries;
• richer datasets;
• superior metadata;
• earlier data releases; or
• better APIs,

competition concerns may arise.

The theory would involve vertical leveraging of infrastructure power into downstream research markets.

11. Case 6: Magill

Court: CJEU
Year: 1991
Cases: Joined Cases C-241/91 P and C-242/91 P

The Magill cases involved refusal to license copyrighted television listings.

The Court recognised exceptional circumstances in which refusal to license intellectual property could constitute abuse.

The decision contributed to the development of the strict framework later refined in IMS Health.

Clinical research relevance

Clinical datasets may involve:

• database rights;
• copyright;
• contractual restrictions;
• trade secrets;
• confidential information.

Ownership rights cannot automatically be treated as absolute shields from competition law.

But Magill also illustrates that exceptional circumstances are necessary.

12. Case 7: Bronner–IMS–Microsoft Line of Authority

Taken together, these cases establish an important principle:

Competition law is particularly concerned where control over a resource moves from ordinary commercial ownership toward genuine infrastructural indispensability.

Clinical-data exchanges could approach this situation where a particular dataset or interoperability layer becomes indispensable for independent research.

13. Data Concentration and Market Foreclosure

A dominant clinical-data intermediary may foreclose competitors through:

A. Exclusive agreements

Hospitals may be contractually prevented from supplying data to rival platforms.

B. Long-term contracts

Five-, ten- or fifteen-year agreements can make market entry difficult.

C. Most-favoured-nation provisions

Hospitals may be restricted from giving better access conditions to competing exchanges.

D. Bundling

Access to clinical data may be conditioned upon purchasing:

• cloud services;
• analytics;
• AI tools;
• cybersecurity services.

E. Self-preferencing

The exchange could favour affiliated research institutions.

14. Data Exclusivity and Pharmaceutical Competition

A particularly significant concern arises where pharmaceutical companies themselves control clinical datasets.

Suppose Company A possesses extensive clinical data concerning a particular disease.

Company A could potentially use that information to:

• accelerate drug development;
• improve patient recruitment;
• identify biomarkers;
• optimise trial design;
• predict adverse events;
• identify acquisition targets.

If competitors cannot access comparable information, the dataset can become a competitive advantage across multiple markets.

15. Research Platforms as Gatekeepers

A clinical-data exchange may evolve from being merely a database into a research gatekeeper.

It may control:

Data → Identity → Authentication → API → Compute → Analytics → Publication.

This creates a vertically integrated research ecosystem.

The competition concern becomes stronger if the same entity controls both:

upstream data infrastructure and downstream research services.

16. Algorithmic Dependency

Modern clinical-data exchanges increasingly incorporate AI.

An exchange may provide:

• predictive models;
• patient-selection algorithms;
• trial recruitment tools;
• disease-risk scoring;
• synthetic-data generation;
• automated cohort identification.

Researchers may therefore become dependent not merely on data but on proprietary computational interpretation of data.

This creates a new form of dependency:

Data dependency + model dependency + infrastructure dependency.

17. Federated Learning and Competition

Federated learning can reduce the need to transfer patient-level data.

Instead:

• hospitals retain their data;
• algorithms travel to the data;
• only permitted outputs are exchanged.

This may improve privacy and security.

However, it can also create new concentration if one platform controls:

• the federated-learning protocol;
• model architecture;
• participating institutions;
• computational infrastructure; and
• access permissions.

Therefore, privacy-enhancing technology does not automatically eliminate competition concerns.

18. Data Portability

Portability can reduce dependency.

Researchers may benefit from:

• machine-readable exports;
• standardised schemas;
• open APIs;
• interoperable identifiers;
• transferable metadata.

Without portability:

switching provider → loss of historical integration → rebuilding research infrastructure.

This produces technical lock-in.

19. Interoperability as a Competition Remedy

Competition authorities may consider remedies such as:

Structural remedies

• divestiture;
• separation of data and analytics businesses;
• independent data trustees.

Behavioural remedies

• non-discriminatory access;
• API access;
• interoperability;
• transparent pricing;
• prohibition on exclusive arrangements.

Governance remedies

• independent oversight;
• researcher representation;
• audit rights;
• data-access committees.

20. Privacy Versus Competition

An important complication is that access cannot simply be ordered without considering:

• GDPR;
• HIPAA;
• national health-data legislation;
• informed consent;
• confidentiality;
• medical ethics;
• cybersecurity;
• cross-border transfer restrictions.

Therefore:

Competition law cannot require unlawful disclosure of personal health information.

The appropriate remedy may instead involve:

• anonymised datasets;
• secure research environments;
• federated queries;
• privacy-preserving computation;
• controlled-access repositories.

21. Cross-Border Dependency

Global clinical-data exchanges create additional jurisdictional problems.

A platform could operate:

United States → European Union → United Kingdom → India → Japan → Singapore.

Different jurisdictions may apply different rules concerning:

• data localisation;
• patient consent;
• health-data processing;
• competition;
• cybersecurity;
• AI;
• research ethics.

A dominant exchange could exploit regulatory fragmentation by shifting infrastructure to jurisdictions with weaker enforcement.

22. Data Localization and Market Fragmentation

Data-localisation requirements can have two opposite effects.

Positive effect

They may protect:

• privacy;
• sovereignty;
• security;
• sensitive health information.

Negative competition effect

They can fragment datasets into national silos.

This may:

• increase entry costs;
• favour large multinational firms;
• reduce cross-border research;
• strengthen incumbents that already possess local infrastructure.

Thus, localisation can unintentionally reinforce concentration.

23. Research Dependency and Academic Freedom

Competition concerns are not limited to commercial pharmaceutical companies.

Universities and public research institutions may also become dependent.

A dominant exchange could theoretically influence:

• which datasets researchers can access;
• research priorities;
• publication conditions;
• replication;
• peer review;
• methodological standards.

This creates a broader concern of scientific infrastructure concentration.

24. Replication as a Competition Principle

Independent replication is particularly important in scientific research.

If researchers cannot independently reproduce:

• datasets;
• analyses;
• model outputs;
• statistical methods,

the dominant data provider may become an epistemic bottleneck.

Competition law normally protects economic competition, not scientific truth as such. Nevertheless, reduced scientific independence may become economically relevant where it affects:

• pharmaceutical innovation;
• medical-device markets;
• clinical-trial competition;
• entry into biotechnology markets.

25. Essential-Facility Analysis

A useful analytical framework is:

The stronger the answers, the stronger the potential competition case.

26. Abuse Through Discriminatory Access

Suppose two pharmaceutical companies request access.

Company A receives:

• real-time data;
• complete metadata;
• unrestricted API access.

Company B receives:

• delayed data;
• incomplete metadata;
• limited queries.

If Company A is affiliated with the exchange, this could raise concerns about discriminatory access and vertical foreclosure.

27. Tying and Bundling

A platform might require researchers to purchase its analytics tools to obtain access to clinical data.

For example:

“You may access the dataset only if you use our cloud environment and our AI analytics platform.”

This could potentially transform data access into a mechanism for extending market power into:

• cloud computing;
• statistical software;
• AI;
• clinical-trial services.

The legal analysis would depend upon dominance, market definition, foreclosure effects, efficiencies and objective justification.

28. Exclusive Data Agreements

Exclusive data agreements deserve particular attention.

A dominant exchange could contract with hospitals:

“All clinical research data generated by this institution must be supplied exclusively to our platform.”

If many major hospitals enter such agreements, rivals may face a cumulative foreclosure problem.

Even if no individual contract is sufficient to foreclose competition, the aggregate effect may be substantial.

29. Killer Acquisition Risks

Clinical-data platforms can also become acquisition targets.

A dominant pharmaceutical or technology company might acquire:

• a clinical-data exchange;
• a genomic database;
• an AI research platform;
• a specialised patient registry.

The acquisition could eliminate an emerging competitor or give the acquirer access to a strategically important dataset.

Thus, merger control becomes an important component of clinical-data competition policy.

30. Data Concentration and AI Drug Discovery

The combination of clinical datasets and AI creates potentially powerful feedback loops:

More patients → more data → better models → more customers → more participating hospitals → more data.

This resembles a data-network effect.

A sufficiently strong feedback loop can produce:

data concentration → model superiority → market concentration → further data concentration.

Competition authorities therefore increasingly need to assess dynamic data advantages, not merely current market shares.

31. Public-Interest and Competition Balance

Clinical data is unusual because it has both:

Commercial value

It can support:

• drug discovery;
• clinical trials;
• diagnostics;
• medical devices;
• AI development.

Public value

It can support:

• public health;
• epidemiology;
• disease surveillance;
• pandemic preparedness;
• academic research.

A competition-law framework should therefore avoid both extremes:

Extreme 1: Treating clinical data as ordinary private property.

Extreme 2: Treating all clinical data as automatically subject to compulsory sharing.

The appropriate approach is proportionate, privacy-preserving and competition-sensitive access.

32. Possible Regulatory Remedies

A. Non-discriminatory access

Equivalent researchers should receive equivalent access conditions.

B. Data portability

Researchers should be able to move datasets where legally permissible.

C. Interoperability

Platforms should support recognised standards.

D. API access

Independent research should not be technically blocked.

E. Data trustees

Sensitive datasets could be administered by independent entities.

F. Firewalls

Data infrastructure could be separated from downstream commercial research.

G. Transparency

Access criteria and pricing should be objectively defined.

H. Auditability

Researchers should have mechanisms for challenging discriminatory decisions.

33. Six Core Legal Principles Emerging From the Case Law

The major cases collectively suggest six principles:

1. Indispensability

Not every valuable dataset is an essential facility.

2. Replicability

The availability of realistic alternatives is crucial.

3. Competition elimination

The effect on competitive opportunities must be demonstrated.

4. Interoperability

Control over technical interfaces can become competitively significant.

5. Vertical leveraging

Infrastructure dominance can potentially be extended into downstream markets.

6. Objective justification

Privacy, security, confidentiality and regulatory obligations can legitimately justify restrictions.

34. Hypothetical Example

Assume Global Clinical Exchange X has agreements with 80% of major hospitals in several countries.

It provides access to a unique longitudinal dataset covering a rare disease.

At the same time, X owns an AI pharmaceutical-research company.

Independent biotechnology firms request access.

X:

• refuses direct access;
• provides delayed aggregate data;
• gives its affiliated research company real-time patient-level access;
• requires competitors to use X's analytics platform; and
• prevents hospitals from supplying data to competing exchanges.

This creates several potential competition issues:

1. dominance in clinical-data infrastructure;
2. exclusive dealing;
3. refusal to supply;
4. discriminatory access;
5. self-preferencing;
6. tying/bundling;
7. vertical foreclosure; and
8. raising rivals' costs.

The strongest legal theory would depend upon proving the relevant market, indispensability, competitive foreclosure and absence of legitimate justification.

35. Key Case-Law Matrix

36. Conclusion

Global clinical data exchanges can become critical infrastructure for modern biomedical competition. Their benefits are substantial, but concentration of data, interoperability standards, authentication systems, analytics and AI capabilities can create significant research dependency.

The central competition-law distinction is between:

valuable data and indispensable infrastructure.

Competition law generally does not require firms to share every proprietary dataset. The exceptional-access cases—particularly Magill, Bronner and IMS Health—establish a demanding threshold. Nevertheless, when a clinical-data exchange becomes genuinely indispensable, controls access to downstream research markets, discriminates between competitors, restricts interoperability or uses data infrastructure to leverage power into adjacent markets, competition concerns become considerably stronger.

The future regulatory challenge is therefore not simply “Who owns the clinical data?” but:

Who controls access to the data, who controls the technical gateway, who controls the analytical layer, and whether independent researchers can realistically compete without that infrastructure?

A sound global framework should combine competition law, data protection, interoperability, portability, research governance and privacy-preserving access mechanisms. The objective should be to prevent data concentration from becoming a permanent barrier to scientific and commercial entry while preserving legitimate patient confidentiality and data-security protections.